Leonard Seibold, MD
Glaucoma Specialist · Aurora, CONPI 1689870164
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. NEW World Medical,inc. accounts for 83.0% of it on its own, with 17 other manufacturers making up the rest. 2025 is the largest year on record at $21,695, 4.6 times the $4,724 reported in 2019.
Across 169 payments — averaging $245.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- NEW World Medical,inc.$34K
- AbbVie$4K
- Alcon$1K
- Thea Pharma Inc.$339
- Aerie Pharmaceuticals, Inc.$201
- Johnson & Johnson Surgical Vision, Inc.$187
- plus $737 from 12 others
Across 38 payments — averaging $3498.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- NEW World Medical,inc.$64K
- AbbVie$52K
- Glaukos Corporation$17K
What the payments were for
- Consulting fees$9,07522%
- Speaking & faculty fees$22,00053%
- Travel & lodging$2,5096%
- Food & beverage$7,80619%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| NEW World Medical,inc. | 86 | $34,428 |
| AbbVie(2 entities) | 21 | $4,283 |
| Alcon | 23 | $1,302 |
| Thea Pharma Inc. | 8 | $339 |
| Aerie Pharmaceuticals, Inc. | 3 | $201 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $187 |
| Bausch & Lomb Americas Inc. | 6 | $123 |
| Eyepoint US, Inc. | 2 | $106 |
| Tarsus Pharmaceuticals, Inc. | 2 | $101 |
| Ocular Therapeutix, Inc. | 2 | $98 |
| Sight Sciences, Inc. | 5 | $97 |
| Oyster Point Pharma, Inc. | 3 | $64 |
| Glaukos Corporation | 1 | $37 |
| Akorn Operating Company LLC | 2 | $33 |
| Dutch Ophthalmic, USA | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| Kala Pharmaceuticals, Inc. | 1 | $17 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$32,094
- Kahook Dual Blade$31,094
- Clearpath$21,547
- Streamline$20,547
- Via360$19,756
- Streamline Surgical System$4,314
- LUMIGAN$2,700
- XEN GLAUCOMA TREATMENT SYSTEM$953
- VUITY$675
- COMBIGAN$675
- ALPHAGAN P$675
- Clareon$243
- IYUZEH$209
- Tecnis IOL$187
- AcrySof$145
- ReSTOR$140
- DURYSTA$125
- Rhopressa$122
- Rocklatan$122
- XEN$100
How this compares
Too few glaucoma specialist providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 259 | $131,541 |
| RestasisCyclosporine | 51 | $66,373 |
| RhopressaNetarsudil Mesylate | 93 | $47,947 |
| XiidraLifitegrast | 18 | $34,292 |
| CombiganBrimonidine Tartrate/Timolol | 72 | $34,224 |
| Alphagan PBrimonidine Tartrate | 59 | $29,423 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 83 | $27,325 |
| Travoprost | 134 | $20,850 |
| RocklatanNetarsudil Mesylat/Latanoprost | 36 | $19,388 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 77 | $16,615 |
| Latanoprost | 931 | $15,142 |
| Cyclosporine | 15 | $13,389 |
| Prednisolone Acetate | 409 | $12,808 |
| Ketorolac Tromethamine | 292 | $11,718 |
| Brinzolamide | 51 | $11,678 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $4,283 | $261,560441 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $201 | $67,334129 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $123 | $45,48445 claims |
| AlconSimbrinza | $1,302 | $27,32583 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Aurora
- Malik KahookAurora$1.3M
- Monica ErtelAurora$7K
- Jeffrey SoohooAurora$5K
- Galia DeitzAurora$1K
- Cara Capitena YoungAurora$824
- Mina PantchevaAurora$719
- Meredith SpitzAurora$498
- Lama AssiAurora$71
- Stephanie MuylaertLittleton$17K
- Micah RothsteinLongmont$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.